JFG
ESPR

Jefferies Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Jefferies Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-63,500
Closed -$149K – 1534
2024
Q1 		$170K Buy
+63,500
New +$154K ﹤0.01% 1368
2023
Q4 		– Sell
-65
Closed -$64 – 1784
2023
Q3 		$64 Sell
65
-112,127
-100% -$162K ﹤0.01% 1567
2023
Q2 		$156K Sell
112,192
-110,828
-50% -$155K ﹤0.01% 1473
2023
Q1 		$355K Sell
223,020
-681,857
-75% -$3.52M ﹤0.01% 1188
2022
Q4 		$5.64M Buy
+904,877
New +$6.47M 0.04% 371

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jefferies Financial Group's ESPR Position: Q2 2024 in Review

Jefferies Financial Group sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 63,500 shares — an estimated $149K sold.

Jefferies Financial Group first reported a position in ESPR in Q4 2022 and held it in 5 quarters. The position peaked at $5.64M in Q4 2022. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Jefferies Financial Group reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 63,500 Esperion Therapeutics shares in Q2 2024, an estimated $149K.
  • Jefferies Financial Group first reported a position in Esperion Therapeutics in Q4 2022 and held it in 5 quarters.
  • Jefferies Financial Group's Esperion Therapeutics position peaked at $5.64M in Q4 2022.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Jefferies Financial Group's 13F filing for Q2 2024, filed 13 Aug 2024.